Skip to main content
. Author manuscript; available in PMC: 2022 Dec 13.
Published in final edited form as: Clin Cancer Res. 2022 Jun 13;28(12):2587–2597. doi: 10.1158/1078-0432.CCR-21-3215

Figure 1. Differentially expressed genes and pathways between pCR and RD in basal-like TNBC treated with neoadjuvant durvalumab and standard of care chemotherapy.

Figure 1.

(A) Volcano plot of differentially expressed genes. Statistically significant genes are in red, top 50 significant genes annotated in blue. (B) Pathway enrichment results. (C) Enrichment score plots of the leading-edge genes from significantly enriched pathways. *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.